Geometric patterns of the left ventricle and cardiometabolic risk in patients with hypertension
Keywords:
hypertension, cardiometabolic risk, left ventricular hypertrophy.Abstract
Introduction: The evaluation of cardiometabolic risk and geometric patterns of the left ventricle in patients with hypertension is vital and constitutes a diagnostic challenge.
Objective: To evaluate the behavior of the geometric patterns of the left ventricle and its relationship with cardiometabolic risk in hypertensive patients.
Methods: Descriptive and cross-sectional research in 70 hypertensive patients. Clinical and metabolic variables of cardiometabolic risk were examined. They were correlated with the time of diagnosis of hypertension, blood pressure control and geometric patterns of the left ventricle.
Results: High levels of total cholesterol, LDL and uric acid were found, as well as concentric remodeling patterns (42.9%) and concentric hypertrophy (31.4%). Concentric remodeling was detected in 40.6% of the overweight and 52.2% of the obese, and concentric hypertrophy was detected in 31.3% of the overweight and 26.1% of the obese. A proportional increase in uric acid was found in remodeling (359.3 ± 84.5), eccentric hypertrophy (373.3 ± 57.0) and concentric hypertrophy (433.3 ± 150.7). The relationship between the time of diagnosis of hypertension and deleterious geometric patterns (concentric hypertrophy 47.1% p = 0.017) was demonstrated. Remodeling predominated in patients with blood pressure control (45.0%). In those who had uncontrolled blood pressure, remodeling (40.0%) and concentric hypertrophy (40.0%) predominated.
Conclusions: Altered geometric patterns were related to worse cardiometabolic risk profiles, uncontrolled blood pressure, and a longer time to diagnosis of hypertension.
Downloads
References
Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020. [acceso 25/07/2023];16(4):223-37. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7998524/
Colectivo de autores. Enfermedades no trasmisibles en Cuba. Tamayo Muñiz S, Pérez Perea L, Pérez González RD, coordinadores. La Habana: Editorial Ciencias Médicas; 2022. [acceso 25/07/2023]. Disponible en: http://www.bvscuba.sld.cu/libro/enfermedades-no-transmisibles-en-cuba/
Pérez Caballero MD, León Álvarez JL, Dueñas Herrera A, Alfonzo Guerra JP, Navarro Despaigne DA, De la Noval García R, et al. Hipertensión arterial. Guía para el diagnóstico, evaluación y tratamiento. 2018. [acceso 25/07/2023];ISBN 978-959-313-643-3. Disponible en: http://www.bvscuba.sld.cu/libro/hipertension-arterial-guia-para-el-diagnostico-evaluacion-y-tratamiento/
Kida K. Left ventricular hypertrophy was not built in a day. Hypertens Res. 2023 [acceso 25/07/2023];46(2):341-2. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36460833/
daSilva-deAbreu A, Alhafez BA, Lavie CJ, Milani RV, Ventura HO. Interactions of hypertension, obesity, left ventricular hypertrophy, and heart failure. Curr Opin Cardiol. 2021 [acceso 25/07/2023];36(4):453-60. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33929365/
Mancia Chairperson G, Kreutz Co-Chair R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. 2023 [acceso 25/07/2023];21. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37345492/
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020 [acceso 25/07/2023];75(6):1334-57. Disponible en: https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.120.15026?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 [acceso 25/07/2023];71(19):e127-248. Disponible en: https://www.ahajournals.org/doi/full/10.1161/HYP.0000000000000065?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Guzik BM, McCallum L, Zmudka K, Guzik TJ, Dominiczak AF, Padmanabhan S. Echocardiography Predictors of Survival in Hypertensive Patients with Left Ventricular Hypertrophy. Am J Hypertens. 2021 [acceso 25/07/2023];34(6):636-44. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33950188/
Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC, et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019 [acceso 25/07/2023];32(1):1-64. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30282592/
Savage DD, Garrison RJ, Kannel WB, Levy D, Anderson SJ, Stokes J 3rd, Feinleib M, Castelli WP. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study. Circulation. 1987 [acceso 25/07/2023];75(1 Pt 2):I26-33. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2947749/
Alamar Cervera M, Lorenzatti D, Ortiz-Pérez JT. Regression of severe left ventricular hypertrophy. Rev Esp Cardiol (Engl Ed). 2022 [acceso 25/07/2023];75(4):343. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34953764/
Srikanthan K, Feyh A, Visweshwar H, Shapiro JI, Sodhi K. Systematic Review of Metabolic Syndrome Biomarkers: A Panel for Early Detection, Management, and Risk Stratification in the West Virginian Population. Int J Med Sci. 2016[acceso 25/07/2023];13(1):25-38. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26816492/
Senarathne R, Hettiaratchi U, Dissanayake N, Hafiz R, Zaleem S, Athiththan L. Metabolic syndrome in hypertensive and non-hypertensive subjects. Health Sci Rep. 2021[acceso 25/07/2023];4(4):e454. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34938898/
Katsimardou A, Imprialos K, Stavropoulos K, Sachinidis A, Doumas M, Athyros V. Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev. 2020 [acceso 25/07/2023];16(1):12-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30987573/
World Health Organization (WHO). Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Technical Report Series No. 854. Geneva: World Health Organization; 1995. [acceso 25/07/2023]. Disponible en: https://apps.who.int/iris/bitstream/handle/10665/37003/W?sequence=1
Tanaka H. Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain. J Echocardiogr. 2021[acceso 25/07/2023];19(2):71-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33460030/
Cosentino F, Verma S, Ambery P, Treppendahl MB, van Eickels M, Anker SD, et al. Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. Eur Heart J. 2023 [acceso 25/07/2023];4:ehad445. Disponible en: https://pubmed.ncbi.nlm.nih.gov/37448181/
Linares-Cánovas L, Lemus-Fajardo N, Linares-Cánovas L, Lazo-Herrera L, Díaz-Pita G. Caracterización de pacientes adultos mayores con tratamiento farmacológico antihipertensivo atendidos en el hospital Dr. León Cuervo Rubio. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta. 2017 [acceso 25/07/2023];42 (6).Disponible en: https://revzoilomarinello.sld.cu/index.php/zmv/article/view/1184
Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Maresova V, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension 2017. [acceso 25/07/2023];69(6):1113–20. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28461599/
Camarena Navarro L, Sáez Méndez L, Castaño Martínez P. Monitorización ambulatoria de la presión arterial en una consulta de medicina interna. Rev Clin Esp. 2016. [acceso 25/07/2023];216(Espec Congr):1199 [Resumen]. Disponible en: https://www.revespcardiol.org/es-congresos-sec-2011-el-2-sesion-riesgo-vascular-hipertension-2840-monitorizacion-ambulatoria-de-la-presion-31571-pdf
Martin TG, Juarros MA, Leinwand LA. Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential. Nat Rev Cardiol. 2023 [acceso 25/07/2023];(5):347-63. Disponible en: https://pubmed.ncbi.nlm.nih.gov/36596855/
de Simone G, Olsen MH, Wachtell K, Hille DA, Dahlof B, Ibsen H, et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens. 2007 [acceso 25/07/2023];21(8):625-32. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17476291/
Hermida RC, Crespo JJ, Otero A, Domínguez-Sardiña M, Moyá A, Ríos MT, et al. Asleep blood pressure: significant prognostic marker of vascular risk and therapeutic target for prevention. Eur Heart J 2018 [acceso 25/07/2023];39(47):4159–71. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30107515/
Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF, et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: The Prospective Urban Rural Epidemiologic (PURE) study. Lancet Glob Health. 2020 [acceso 25/07/2023];19;7(6):e748-60. Disponible en: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(19)30045-2/fulltext
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021 [acceso 25/07/2023];398(10304):957-80. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34450083/
Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Arch Cardiovasc Dis. 2021 [acceso 25/07/2023];114(2):132-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33546998/
Senarathne R, Hettiaratchi U, Dissanayake N, Hafiz R, Zaleem S, Athiththan L. Metabolic syndrome in hypertensive and non-hypertensive subjects. Health Sci Rep. 2021 [acceso 25/07/2023];4(4):e454. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34938898/
Al Shehri HA, Al Asmari AK, Khan HA, Al Omani S, Kadasah SG, Horaib GB, et al. Association between preventable risk factors and metabolic syndrome. Open Med (Wars). 2022 [acceso 25/07/2023];17(1):341-52. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35415246/
García Sánchez N, León Álvarez JL. Biomarcadores de la arteriosclerosis como predictores del riesgo cardiovascular en la hipertensión arterial no complicada. RCAN Rev Cubana Aliment Nutr 2016 [acceso 25/07/2023];26(2): 275-83. Disponible en: http://www.revalnutricion.sld.cu/index.php/rcan/article/view/67
Madariaga Galvis WE, Donis JH. Prevalencia de los patrones geométricos el ventrículo izquierdo en una población de hipertensos tratados: efecto de la edad, sexo, índice de masa corporal, control de la presión arterial y tratamiento. Revista Venezolana de Endocrinología y Metabolismo. 2015 [acceso 25/07/2023];13(3):156–63. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1690-31102015000300004&lang=es
Moustafa MM, RezK AA, Marghany KA, Sayed AY. Electrocardiography versus echocardiography for assessment of left ventricular hypertrophy in ischemic heart disease patients with and without cardiovascular risk factors. The Egyptian J Hosp Medicine. 2019 [acceso 25/07/2023];74(5):1165-73. Disponible en: https://ejhm.journals.ekb.eg/article_26382_90414189a142404dc7d7ea292fde4504.pdf
Luque M, Galgo A, Abad E, Cea-Calvo L, Fernández-Pérez C, Navarro J, et al. Hipertrofia ventricular izquierda por electrocardiografía o ecocardiografía y complicaciones cardiovasculares en hipertensos tratados de la comunidad autónoma de Madrid. Estudio MAVIS-HTA. Hipertensión. 2008 [acceso 25/07/2023];25(3):99-107. Disponible en: https://www.sciencedirect.com/science/article/abs/pii/S0212824108708818
Khaznadar AA, Ahmed FJ, Tahir K, Kakamad FH. Left ventricular hypertrophy in hypertensive patients: Prevalence and diagnosis. Edorium J Cardiol 2018 [acceso 25/07/2023];4:100008C03AK2018. Disponible en: https://www.edoriumjournalofcardiology.com/archive/2018-archive/2018-articles-archive/100008C03AK2018-Khaznadar/100008C03AK2018-Khaznadar-full-text.php
Cuspidi C, Rescaldani M, Sala C, Grassi G. Left-ventricular hypertrophy and obesity: a systematic review and meta-analysis of echocardiographic studies. J Hypertens. 2014 [acceso 25/07/2023];32(1):16-25. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24309485/
González Jardinez M, López de Villavicencio Hernández I. Modificaciones en el patrón geométrico y la función cardíaca asociadas a malnutrición por exceso. 2020 [acceso 25/07/2023] Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-03002020000400013
Iyengar SS, Ram CVS. Concentric vs. Eccentric Left Ventricular Hypertrophy: Does It Matter? It Is All "Blood Pressure Centered". Am J Hypertens. 2021 [acceso 25/07/2023];34(6):581-2. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33950166/
Murdolo G, Angeli F, Reboldi G, Di Giacomo L, Aita A, Bartolini C, et al. Left ventricular hypertrophy and obesity: only a matter of fat? High Blood Press Cardiovasc Prev. 2015 [acceso 25/07/2023];22(1):29-41. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25117210/
Gerdts E, Cramariuc D, de Simone G, Wachtell K, Dahlof B, Devereux R. Impact of left ventricular geometry on prognosis in hypertensive patient with left ventricular hypertrophy (The LIFE study). Eur J Echocardiogr. 2008 [acceso 25/07/2023];9(6):809-15. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18490279/
Cuspidi C, Facchetti R, Bombelli M, Tadic M, Sala C, Grassi G, Mancia G. High Normal Blood Pressure and Left Ventricular Hypertrophy Echocardiographic Findings from the PAMELA Population. Hypertension 2019 [acceso 25/07/2023];73(3):612–9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30612493/
Downloads
Published
How to Cite
Issue
Section
License
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
